AOD-9604 vs GLP-1 Agonists — Two Philosophies of Fat Metabolism

Two Completely Different Philosophies

AOD-9604 and GLP-1 agonists both appear in the OSYRIS Metabolic category, but they represent fundamentally different approaches to studying fat metabolism:

AOD-9604 acts on fat tissue directly. It activates beta-3 adrenergic receptors on adipocytes, triggering hormone-sensitive lipase to release fatty acids from stored triglycerides. It also inhibits lipogenic enzymes, reducing new fat synthesis. AOD-9604 doesn't affect appetite, insulin, glucose, or IGF-1 — it's a targeted intervention on adipose tissue metabolism.

GLP-1 agonists act on the brain and pancreas. They suppress appetite through hypothalamic and brainstem signaling, enhance glucose-dependent insulin secretion, and slow gastric emptying. Fat loss occurs as a downstream consequence of reduced caloric intake — not through direct action on fat cells.

These mechanisms are not just different — they're orthogonal. One targets the supply side (how much fat is stored and mobilized). The other targets the demand side (how much food is consumed). This orthogonality makes combination research conceptually rational: could targeting both simultaneously produce effects beyond either approach alone?

The Evidence Gap

GLP-1 agonists have dramatically stronger clinical evidence. Phase 3 trials with thousands of participants show 15-24% body weight reduction. The evidence is robust, replicated, and FDA-approved.

AOD-9604's clinical evidence is weaker. The Phase 2 oral trial confirmed safety but didn't meet its primary weight loss endpoint. Whether this reflects the compound's biology or the trial design (oral delivery of a peptide, potentially suboptimal dosing) is debated.

In preclinical models (obese Zucker rats), AOD-9604 clearly reduces body fat. The preclinical-to-clinical translation gap remains the main question mark.

When to Use Which

GLP-1 agonists for protocols studying incretin signaling, appetite biology, glucose metabolism, or when the strongest available clinical evidence base is required.

AOD-9604 for protocols requiring direct adipose tissue intervention without appetite or insulin confounders, for studying GH-fragment biology specifically, or for fat metabolism research where central appetite signaling is not the variable of interest.

Both for combination protocols testing whether direct lipolysis + appetite suppression produces additive effects.